Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IGV 001

Next Previous
X
Search
Drug Profile

IGV 001

Alternative Names: IGF-1R antisense therapy; IGF-1R/AS ODN; IGV-001; Insulin growth factor receptor type 1 antisense therapy; Type 1 insulin growth factor receptor antisense therapy

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Thomas Jefferson University
  • Developer Imvax; Thomas Jefferson University
  • Class Antineoplastics; Antisense oligonucleotides; Cancer vaccines; Immunotherapies; Tumour cell vaccines
  • Mechanism of Action CD4-positive T-lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • No development reported Solid tumours

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (SC)
  • 22 May 2024 IGV 001 receives Fast Track designation for Glioblastoma [SC,Implant] (First-line therapy) in USA
  • 22 May 2024 Imvax completes enrolment in its phase II trial Glioblastoma (Combination therapy, Late-stage disease, First-line therapy) in USA (SC) (NCT04485949)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top